Evidence map›Paper›PMID 34850058›Full record

ArticleJournal of the National Cancer Institute2022

RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.

Michael Mark, Roger von Moos, Richard Cathomas, Sandro Stoffel, Silke Gillessen

Open access · bronzeAbstract readComment
In one paragraph

Article in Journal of the National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Michael MarkDepartment of Haematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland.
Roger von MoosDepartment of Haematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland.
Richard CathomasDepartment of Haematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland.
Sandro StoffelInstitute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland.
Silke GillessenEOC-Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
Kantonsspital Graubünden · CHUniversità della Svizzera italiana · CHUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone NeoplasmsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantCastrationHumansMale

Identifiers

PMID34850058
PMCPMC9002272
OpenAlexW3216965649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.